COMMUNIQUÉS West-GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
25/08/2025
HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET. Attendees will [...]
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
25/08/2025
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other [...]
Husband Material Ministries Announces New Book by Drew Boa: "Outgrow Porn: Find Lasting Freedom Without Fighting an Exhausting Battle—A Man's Guide to Healing"
25/08/2025
Empowering Men to Overcome Pornography Addiction Colorado Springs, CO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Husband Material Ministries , a leading nonprofit organization dedicated to helping men find lasting freedom from [...]
Baylor Genetics to Showcase RNA Sequencing Breakthroughs for Rare Disease Diagnosis at 2025 AGBT Precision Health Meeting
25/08/2025
Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease Care HOUSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of [...]
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
25/08/2025
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure [...]
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
25/08/2025
Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics [...]
Climb Bio to Present at Upcoming September 2025 Investor Conferences
25/08/2025
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its [...]
EDAP to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
25/08/2025
AUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate [...]
Jade Biosciences to Participate in Upcoming Conferences
25/08/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune [...]
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
25/08/2025
Financing will enable the completion of the ongoing Phase 1/2 clinical trial of INX-315 in patients with recurrent advanced/metastatic cancer RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio [...]
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
25/08/2025
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need [...]
Propanc Biopharma Provides Shareholder Update
25/08/2025
MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from [...]
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
25/08/2025
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one [...]
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
25/08/2025
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in [...]
Spectral Medical Receives US$3 Million From Vantive
25/08/2025
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that [...]
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
25/08/2025
US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+ TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer Expands Bria-OTS+ novel [...]
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
25/08/2025
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need [...]
OneMedNet Expands Multiple Revenue-Delivering Projects Under Evergreen Agreement With Top Medical Device Leader
25/08/2025
MINNEAPOLIS, Aug. 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announces significant adoption by one [...]
Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
25/08/2025
Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple [...]

Pages